Nitric oxide (NO) is synthesized from L-arginine and molecular oxygen by a family of three enzymes: NOS1, NOS2, and NOS3. NO is the most powerful endogenous vasodilator known. It can also inhibit the adhesion, aggregation, and recruitment of platelets; inhibit vascular smooth muscle cell migration and growth; regulate some vessel–platelet interactions; and limit the oxidation of atherogenic low-density lipoproteins. These actions are all mediated by the activation of soluble guanylate cyclase and the consequent increase in the concentration of cyclic GMP in target cells.

The constitutive endothelial nitric oxide synthase (NOS3) is expressed in the endothelium and is encoded by a 26-exon gene located on chromosome 7q35 to 36; the gene, with a total size of 21 kb, encodes an mRNA of 4052 nucleotides. The NOS3 gene is expressionally and functionally regulated through multiple regulatory steps and entails several polymorphisms, some of which bear functional consequences. Reduction in basal NO release is known to predispose humans to atherosclerosis, hypertension, thrombosis, and vasospasm. On the other hand, high circulating NO concentrations, which occur with excessive in-
ducible NOS expression under pathological conditions, are generally toxic. Emerging evidence suggests that coronary artery disease (CAD) is related to defects in the generation or function of NO. Markedly increased NO concentrations are reported to be associated with endotoxic shock and exaggerated inflammatory reactions, which may lead to acute hepatic dysfunction and predispose humans to asthma and cardiomyopathy.

In general, NOS3 gene polymorphisms have been reported to act as ‘susceptibility genes’ in various cardiovascular and pulmonary diseases. GT substitution in exon 7 of codon 298, 4a/b polymorphism in intron 4, T-786C mutation in the 5′-flanking region, and high numbers of CA repeat in intron 13 of the NOS3 gene are also associated with an excess risk for CAD. Among them, a common variant located in exon 7 (G984T) of the NOS3 gene that modifies its coding sequence (Glu298Asp) has been linked by several groups to the risk for CAD and acute myocardial infarction (MI). On the other hand, other studies failed to show any relationship between the Asp variant and the risk for atherosclerosis. In the present study, we investigated the associations between the occurrence and severity of angiographically defined CAD and the Glu298Asp polymorphism.

SUBJECTS AND METHODS

Patients recruited in this study (n=241; 174 males and 67 females) were those who had undergone coronary angiography because of recent MI or angina. They were selected at Tehran Shahid Rajaee Heart Hospital after being angiographically identified (>50% stenosis affecting at least one coronary vessel) as having CAD. The control group consisted of 261 individuals (187 males and 74 females) within the same age range as the patients; they were selected at the same hospital after screening to eliminate individuals with a history of chest pain, diabetes, hypertension, or any other specific illness. Clinical details of these groups are shown in Table 1. All participants were interviewed and data on smoking habits, blood pressure, lipid profile, and any family history of diabetes, hypertension, or any other specific illness were collected at Tehran Shahid Rajaee Heart Hospital after being angiographically identified (>50% stenosis affecting at least one coronary vessel) as having CAD. The control group consisted of 261 individuals (187 males and 74 females) within the same age range as the patients; they were selected at the same hospital after screening to eliminate individuals with a history of chest pain, diabetes, hypertension, or any other specific illness. Clinical details of these groups are shown in Table 1. All participants were interviewed and data on smoking habits, blood pressure, lipid profile, and any family history of CAD were recorded. The study protocol was approved by the Ethics Committee of Iran University of Medical Sciences and written informed consent was taken from all patients and healthy individuals.

Blood samples were obtained from all subjects after 12 hours of fasting and placed in EDTA tubes and stored at −70°C until the time of assay. Serum concentrations of triglyceride (TG), total cholesterol, low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) were measured by standard enzymatic methods (ZiestChem Diagnostics, Iran) in the clinical laboratory of the hospital. Genomic DNA was tracted from peripheral blood leukocytes by a standard method (Roche Blood Kit, Germany). Two oligonucleotide primers (sense) 5′-GAC CCT GGA GAT GAA GGC AGG AGA-3′ and (antisense) 5′-ACC TCC AGG ATG TTG TAG CGG TGA-3′ based on the flanking sequences of the exon 7 in the NOS3 gene were used to amplify the corresponding DNA fragment by the polymerase chain reaction (PCR). The reaction was performed in a 25-µl final volume and contained 2.5 pmol of each primer, 0.2 mmol of each deoxynucleoside triphosphate (Roche, Germany), 1.5 U Tag DNA polymerase (Fermentas, Lithuania), 50 mmol/l KCL, 2.5 mmol/l MgCl2, 10 mmol/l Tris-Hcl (pH=8.3), and 400 ng of genomic DNA. The reaction was done according to the following protocol: initial denaturation at 94°C for 5 min, 30 cycles of denaturation at 94°C for 30 s, annealing at 61°C for 30 s, extension at 72°C for 30 s, and final extension at 72°C for 6 min. The 517-bp PCR fragments were digested with BanII restriction enzyme for 16 hours at 37°C. The wild-type allele (G) has no BanII cleavage site, whereas the PCR product was cleaved into two fragments of 346 and 171 bp in the presence of the T984.

All statistical analysis was performed with SPSS v. 11.5. Numeric data are presented as mean (standard deviation) and compared using Student’s t-test. The categorical variables were compared by the chi-square test. The relationship between the variables was analyzed by using the linear regression model. The level of significance was set at P<0.05.

Table 1. Clinical characteristics of the studied population.

|                       | CAD patients | Controls | P value |
|-----------------------|--------------|----------|---------|
| No. of subjects       | 241          | 261      |         |
| Age (years)           | 53.3 (9.4)   | 51.8 (8.9) | NS |
| BMI (kg/m²)           | 27.1 (6.1)   | 27.5 (19.9) | NS |
| Smoking n (%)         | 88 (36.5)    | 66 (25.3)  | 0.004 |
| Family history n (%)  | 92 (38)      | 68 (26)   | 0.002 |
| DBP (mm Hg)           | 85.4 (13.6)  | 76 (6.7)  | 0.001 |
| SBP (mm Hg)           | 129.9 (24.3) | 117.5 (139)| 0.001 |
| Cholesterol (mg/dl)   | 203.8 (45.6) | 188.1 (32.3)| 0.001 |
| TG (mg/dl)            | 204 (110.5)  | 193.3 (10.7) | 0.001 |
| LDL-C (mg/dl)         | 116.9 (37.2) | 105.6 (33.7) | 0.001 |
| HDL-C (mg/dl)         | 46.9 (10.4)  | 48.3 (10.8) | NS |
| LDL-C/HDL-C           | 2.63 (0.93)  | 2.34 (0.88) | 0.006 |

Values are mean (SD); BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood pressure; TG=triglyceride; LDL-C=LDL cholesterol; HDL-C=HDL cholesterol; NS=non-significant.
deviation). The differences between groups were examined by the chi-square test or an independent t test as appropriate. ANOVA was used for comparisons among the three groups. Allele frequencies were estimated by the gene-counting method. The frequencies of the alleles and genotypes were compared between patient and control groups by the chi-square test when appropriate. The odds ratio (OR) and 95% confidence intervals (CI) were also estimated. The chi-square test was used to examine the deviation of genotype distribution from the Hardy-Weinberg equilibrium. Logistic regression analysis was used to assess the independent effect of each risk factor in CAD.

RESULTS
The clinical characteristics of the population are shown in Table 1. Control subjects were matched to the case patients by gender and age. Although BMI and HDL-C showed no significant differences between the patients and the control subjects, systolic blood pressure (SBP) and diastolic blood pressure (DBP), triglyceride, total cholesterol, LDL-C, and LDL-C/HDL-C in patients were significantly higher. The frequency of cigarette smoking and family history of CAD in patients were higher than in controls.

The genotype frequencies of Glu298Asp polymorphism in control subjects were 61.3% for Glu/Glu, 32.2% for Glu/Asp, and 6.5% for Asp/Asp. On the other hand, in CAD patients, the genotype frequencies were 46.5% for Glu/Glu, 42.7% for Glu/Asp, and 10.8% for Asp/Asp (Table 2). Although the distribution of genotypes in both the CAD and the control groups satisfied the Hardy-Weinberg equilibrium, the G894T polymorphism of the NOS3 gene was significantly associated with the presence of CAD in our patients ($\chi^2=11.5$, $P=.003$).

The frequencies of the Glu and Asp alleles were 32.2% and 67.8% for CAD patients and 22.6% and 77.4% for the control subjects, respectively; the differences between the groups were statistically significant ($\chi^2=11.6$, $P=.001$, odds ratio=1.6). We analyzed the frequencies of Glu/Asp and Asp/Asp genotypes in CAD patients and control subjects according to age (age ≤55 years and age >55 years) and found that the frequencies of Glu/Asp and Asp/Asp genotypes were significantly higher in patients of age ≤55 years ($\chi^2=30.3$, $P=.000$, odds ratio=3.84) (Table 3). The logistic regression analysis revealed that the NOS3 mutant allele, smoking, family history, DBP, and LDL-C were independent risk factors for CAD ($P=.004$, $P=.001$, $P=.006$, $P=.001$, and $P=.001$, respectively), whereas DBP, cholesterol, HDL-C, and TG were not independent risk factors for CAD (Table 4).

DISCUSSION
In addition to established risk factors, genetic risk factors may have important roles in the pathogenesis of coronary atherosclerosis and acute MI. Using the

| Table 2. Genotype and allele frequencies of Glu298Asp polymorphism of the eNOS gene in CAD patients and controls. |
|------------------|---------------|-----------------|-----|-----|
|                  | CAD patients  | Controls        | Odds ratio (95% CI) | $P$ value | $\chi^2$ |
| Glu298 Asp polymorphism |                |                 |                  |          |          |
| Glu/Glu, n (%)    | 112 (46.5)    | 160 (61.3)      | 1.83 (1.28-2.6)   | .001     | 111.1    |
| Glu/Asp, n (%)    | 103 (42.7)    | 84 (32.2)       |                   |          |          |
| Asp/Asp, n (%)    | 26 (10.8)     | 17 (6.5)        |                   |          |          |
| Total             | 241           | 261             |                   |          |          |

| Table 3. Genotype frequencies of Glu298Asp polymorphism of the eNOA gene in CAD patients and controls in different ages. |
|------------------|---------------|-----------------|-----|
|                  | CAD patients  | Controls        | Odds ratio (95% CI) | $P$ value | $\chi^2$ |
| Glu298Asp polymorphism |                |                 |                  |          |          |
| Age ≤55 years    |                |                 |                  |          |          |
| Glu/Glu, n (%)   | 36 (28)        | 104 (60)        | 3.84 (2.4-6.3)    | .001     | 30.3     |
| Glu/Asp+Asp/Asp, n (%) | 93 (72)    | 70 (40)         |                   |          |          |
| Total             | 129           | 174             |                   |          |          |
| Age >55 years    |                |                 |                  |          |          |
| Glu/Glu, n (%)   | 76 (68)        | 56 (64)         | 0.86 (0.47-1.56)  | .6       | 0.27     |
| Glu/Asp+Asp/Asp, n (%) | 36 (32)    | 31 (36)         |                   |          |          |
| Total             | 112           | 87              |                   |          |          |
approach of epidemiological studies, it is possible to identify weak susceptible genes in polygenic diseases like coronary heart disease. In the last decade, the potential link between an increasing number of gene variants and coronary heart disease has been analyzed by several investigators. Due to the protective roles of NO against important events during atherogenesis, the NOS3 gene has been identified as also having other roles in deciding susceptibility to coronary heart disease.

There are many polymorphisms of the NOS3 gene that have been investigated in relation to CAD. Yashimura et al described a point mutation of guanine to thymine at nucleotide 1998 in exon 7 of the NOS3 gene that resulted in replacement of glutamic acid by aspartic acid at codon 298. Later investigations also described other polymorphisms in the 5’ flanking and some introns of the NOS3 gene. Other studies analyzed the relation of the NOS3 gene variation with the risk of CAD. In an Australian population, Cai et al did not detect any association between NOS3 gene polymorphism and the risk of CAD. In our previous study, we found that 4a/b polymorphism was not an independent risk factor for CAD in our population.

In the present study, we have shown that Glu298Asp polymorphism is an independent risk factor for CAD in this Iranian population, especially in younger patients (age≤55 years).

In conclusion, our results show that genotype frequencies for Glu/Glu, Asp/Glu, and Asp/Asp, and also Asp allele frequency, are significantly different between individuals with and without CAD. We have also shown that the Asp allele of NOS3 Glu298Asp polymorphism and DBP are independent risk factors for CAD. In our study, the sample size was small thus; a larger number of patients and controls needs to be examined to confirm the association between this polymorphism and CAD.

Acknowledgments
This work was supported by the grant from research section of Iran University of Medical Sciences and performed in Cellular and Molecular Research Center of the Zahedan University of Medical Sciences.
REFERENCES

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.

2. Wang Y, Marsden PA. Nitric oxide synthase: biochemical and molecular regulation. Curr Opin Nephrol Hypertens 1995;4:12-22.

3. Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 1988;12:511-8.

4. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hali AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268:17478-88.

5. Nadaud S, Bonnardeaux A, Latrop M, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun 1994;198:1027-33.

6. Yoon S, Moon J, Shin C, Kim E, Jo SA, Jo I. Smoking status-dependent association of the 27-bp repeat polymorphism in intron 4 of endothelial nitric oxide synthase gene with plasma nitric oxide concentrations. Clin Chim Acta 2002;324:113-20.

7. Kone BC. Molecular biology of nitric oxide synthase and nitric oxide synthase. Cardiovasc Res 2002;51:429-41.

8. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-9.

9. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polytetradecanucleotide (GTGAA)-3 repeats and nitric oxide synthase. Cardiovasc Res 1997;38:87-104.

10. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. J Biol Chem 1999;274:521-6.

11. Hingorani AD, Liang CF, Fatibene J, Lyon A, Montefelt S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase gene (Glu298Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1998;100:1515-20.

12. Yama Y. Risk factors for Coronary artery spasm: significance of endothelial nitric oxide synthase gene. J Invest Med 2000;48:367-74.

13. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T786C mutation in the 5-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864-70.

14. Stangl K, Cascarci I, Laule M, Klein T, Stangl V, Rost S, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenet 2000;10:133-40.

15. Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Massetti S, et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298Asp) to the presence, extent, and severity of coronary artery disease. Heart 2002;87:525-8.

16. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998;32:521-6.

17. Umbach DM, Weinberg CR. Designing and analyzing case-control studies to exploit independence of genotype and exposure. Stat Med 1997;16:1731-43.

18. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. J Biol Chem 1999;274:241-5.

19. Loscalzo J, Welch G. Nitric oxide and its role in cardiovascular system. Prog Cardiovasc Dis 1995;38:87-104.

20. Cai H, Wilcken DE, Wang XL. The Glu298Asp mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med 1999;77:511-4.

21. Lembo G, De Luca N, Battaglì C, Iovino G, Aretini A, Muscico M, et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001;32:735-40.

22. Gardemann A, Lohre J, Cayci S, Katz N, Tillmanns H, Hafner W, The T allele of the missense Glu298Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis 2002;166:167-75.

23. Nassar BA, Bevin LD, Johnstone DE, O’Neill SJ, Bata IR, Kirkland SA, et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am J Hum Genet 2001;142:596-9.

24. Schmolzer I, Renner W, Paulweber B, Malaimare L, Iglceder S, Schmid P, et al. Lack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest 2003;33:191-8.

25. Jaramillo PC, Mutlic Í MA, Lanas MC, Lanas ZF, Salazar LA. Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls. Clin Chim Acta 2006;371:102-5.

26. Kerkani M, Addad F, Chauffert M, Myara A, Ben Farhat M, Milled A, et al. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin Chem 2006;52:53-8.

27. Cam SF, Sekuri C, Tengiz I, Erçan E, S醜can A, Akin M, et al. The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population. Thromb Res 2005;116:87-92.

28. Berdeli A, Sekuri C, Sirri Cam F, Erçan E, S醜can A, Tengiz I, et al. Association between eNOS(Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population. Clin Chim Acta 2005;351:97-104.

29. Salimi S, Firoozi M, Nourmohammadi I, Shahbani M, Mohbibi A. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with coronary artery disease in Iran. Indian J Med Res 2008;124:883-8.

30. Srivastava K, Biswas UK, Narang R, Varghese JJ, Das N. Prevalence of NOS3 Glu298Asp polymorphism in healthy volunteers from a region of Northern India. Community Genet 2005;8:180-3.